Interesting Life Sciences News
09th July 2019
Milestone for BioNTech: 325 Million USD for further development of its cancer immunotherapy.
22nd April 2019
Eli Lilly and Avidity Biosciences announce licensing & research cooperation on combined monoclonal antibodies and oligonucleotide-based therapies for potential new medicines in immunology and other select indications.
01st November 2018
llumina acquires Pacific Biosciences for approximately $1.2 Billion
Milestone for BioNTech: 325 Million USD for further development of its cancer immunotherapy.
22nd April 2019
Eli Lilly and Avidity Biosciences announce licensing & research cooperation on combined monoclonal antibodies and oligonucleotide-based therapies for potential new medicines in immunology and other select indications.
01st November 2018
llumina acquires Pacific Biosciences for approximately $1.2 Billion
Our Mission, Technology & Key Products
As leading pioneer in high-end nucleic acid modification & conjugation, we understand ourselves as transformative enabler for the development of new and value added applications, e.g. single-molecule NGS sequencing, best-in-class cell proliferation tests, engineered mRNA,…
Based on our perfected bioconjugation concept, we offer ready-to-use clickable products, custom oligos as well as our powerful technology next to product development services.